Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay

被引：1
|
作者：
Parikh, A. [1 ]
van Seventer, E. [2 ]
Boland, G. [1 ]
Siravegna, G. [1 ]
Hartwig, A. [3 ]
Jaimovich, A. [4 ]
Raymond, V. M. [5 ]
Talasaz, A. [6 ]
Corcoran, R. B. [7 ]
机构：
[1] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[3] Guardant Hlth Inc, Res & Dev, Redwood City, CA USA
[4] Guardant Hlth Inc, Bioinformat, Redwood City, CA USA
[5] Guardant Hlth Inc, Med Affairs, Redwood City, CA USA
[6] Guardant Hlth Inc, Redwood City, CA USA
[7] MGH Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [31] Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
    Zhu, Lemei
    Xu, Ran
    Yang, Leilei
    Shi, Wei
    Zhang, Yuan
    Liu, Juan
    Li, Xi
    Zhou, Jun
    Bing, Pingping
    FRONTIERS IN GENETICS, 2023, 14
  • [32] A patient-specific, tumor-informed, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay in surgical patients with biliary tract cancer
    Song, Tianqiang
    Wu, Qiang
    Cui, Yunlong
    Li, Huikai
    Zhang, Wei
    Fang, Feng
    Xiong, Qingqing
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
    Cao, Di
    Wang, Fu-Long
    Li, Cong
    Zhang, Rong-Xin
    Wu, Xiao-Jun
    Li, Liren
    Lu, Zhen-Hai
    Pan, Zhi-Zhong
    Lin, Jun-zhong
    Wu, Miaoqing
    Liu, Yifan
    Lv, Guangzhao
    Li, Min
    Wang, Chenyang
    Li, Xi
    Chen, Gong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 213 - 213
  • [34] Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)
    Isbell, James M.
    Goldstein, Jordan Scott
    Hamilton, Emily G.
    Liu, Si-Yang
    Eichholz, Jordan
    Buonocore, Darren J.
    Rusch, Valerie W.
    Bott, Matthew
    Molena, Daniela
    Rocco, Gaetano
    Yang, Soo-Ryum
    Rudin, Charles M.
    Jones, David R.
    Roff, Alanna
    Schultz, Andre
    Chabon, Jake J.
    Kurtz, David Matthew
    Alizadeh, Ash A.
    Li, Bob T.
    Diehn, Maximilian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Circulating Tumor DNA as a Marker of Minimal Residual Disease in Colorectal Cancer
    Kopetz, Scott
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 791 - 793
  • [36] Utility of circulating tumor DNA (ctDNA) for detection of minimal residual disease (MRD) after curative-intent therapy in localized pancreatic cancer (PDAC)
    Yanala, Ujwal R.
    Martos, Mary
    Dickey, Erin M.
    Corona, Andres
    Ezenwajiaku, Nkiruka
    Pizzolato, Joseph
    Terrero, Gretel
    Hester, Caitlin A.
    Merchant, Nipun
    Hosein, Peter
    Datta, Jash
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S23 - S24
  • [37] Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
    Emiloju, Oluwadunni E.
    Storandt, Michael
    Zemla, Tyler
    Tran, Nguyen
    Jethwa, Krishan
    Mahipal, Amit
    Mitchell, Jessica
    Thiels, Cornelius
    Mathis, Kellie
    McWilliams, Robert
    Hubbard, Joleen
    Sinicrope, Frank
    Shi, Qian
    Jin, Zhaohui
    JCO PRECISION ONCOLOGY, 2024, 8
  • [38] Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma
    Ueberroth, Benjamin E.
    Jones, Jeremy C.
    Bekaii-Saab, Tanios S.
    PANCREATOLOGY, 2022, 22 (06) : 741 - 748
  • [39] Circulating tumor DNA (ctDNA) for detection of molecular residual disease (MoRD) in breast cancer
    Austin, L.
    Jaslow, R.
    Fortina, P.
    Nagy, R.
    Zill, O.
    Talasaz, A.
    Cristofanilli, M.
    CANCER RESEARCH, 2016, 76
  • [40] Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective study (TRACC)
    Anandappa, Gayathri
    Starling, Naureen
    Begum, Ruwaida
    Bryant, Annette
    Sharma, Shruti
    Renner, Derrick
    Aresu, Maria
    Peckitt, Clare
    Sethi, Himanshu
    Feber, Andrew
    Potter, Vanessa Alice
    Paraoan, Marius
    Abulafi, Muti
    George, Nicol
    Branagan, Graham
    Duff, Sarah
    West, Nicholas
    Aleshin, Alexey
    Chau, Ian
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345